Prana Biotechnology Limited develops therapies for the treatment of Alzheimer's disease, Huntington disease, and other neurodegenerative disorders in Australia. Its lead drug candidates include PBT2, which is in Phase IIb clinical trials for the treatment of Alzheimer's: and that is in Phase IIa clinical trials for the treatment of Huntington's diseases. The company is also developing PBT434, which is in preclinical toxicology stage for the treatment for Parkinson's disease and other movement disorders; and PBT 519 that is in preclinical toxicology stage for the treatment of brain cancer. It also has a library of approximately 1000 metal protein attenuating compounds. The company has a research collaboration agreement with Takeda Pharmaceuticals International, Inc. to slow or prevent neurodegeneration of the gastrointestinal system through PBT434, an investigational movement disorders compound. Prana Biotechnology Limited was founded in 1997 and is based in Melbourne, Australia.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:PRAN
CUSIPN/A
Phone61-3-9349-4906
Debt
Debt-to-Equity RatioN/A
Current Ratio12.11
Quick RatioN/A
Price-To-Earnings
Trailing P/E Ratio-3.19
Forward P/E Ratio-2.55
P/E GrowthN/A
Sales & Book Value
Annual Sales$100,000.00
Price / Sales181.56
Cash FlowN/A
Price / CashN/A
Book Value$2.01 per share
Price / Book1.01
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A
Miscellaneous
Employees9
Outstanding Shares8,900,000
Market Cap$19.31 million
Prana Biotechnology (NASDAQ:PRAN) Frequently Asked Questions
What is Prana Biotechnology's stock symbol?
Prana Biotechnology trades on the NASDAQ under the ticker symbol "PRAN."
When is Prana Biotechnology's next earnings date?
What price target have analysts set for PRAN?
1 analysts have issued 1 year price targets for Prana Biotechnology's stock. Their forecasts range from $4.00 to $4.00. On average, they expect Prana Biotechnology's stock price to reach $4.00 in the next year. This suggests a possible upside of 96.1% from the stock's current price. View Analyst Price Targets for Prana Biotechnology.
What is the consensus analysts' recommendation for Prana Biotechnology?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Prana Biotechnology in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Prana Biotechnology.
Who are some of Prana Biotechnology's key competitors?
Some companies that are related to Prana Biotechnology include Advaxis (ADXS), Neurotrope (NTRP), Pharmaxis Limited ADR Common Stock (PXSLY), Aquinox Pharmaceuticals (AQXP), IMMUTEP LTD/S (IMMP), KemPharm (KMPH), Merrimack Pharmaceuticals (MACK), OASMIA PHARMACE/ADR (OASM), Trillium Therapeutics (TRIL), VIVUS (VVUS), Novan (NOVN), Alimera Sciences (ALIM), SCYNEXIS (SCYX), Imprimis Pharmaceuticals (IMMY) and Axsome Therapeutics (AXSM).
Who are Prana Biotechnology's key executives?
Prana Biotechnology's management team includes the folowing people:
- Mr. Geoffrey Paul Kempler B.Sc, Grad.Dip.App.Soc.Psych, Co-Founder, Exec. Chairman, CEO & MD (Age 63)
- Ms. Kathryn Andrews B.Com, CPA, Chief Financial Officer (Age 51)
- Ms. Dianne M. Angus, Chief Operating Officer (Age 58)
- Dr. David A. Stamler M.D., Chief Medical Officer, Sr. VP of Clinical Devel. and Member of R&D Advisory Board (Age 57)
- Prof. Rudolph Emile Tanzi Ph.D., Chief Scientific Advisor and Member of R&D Advisory Board
Has Prana Biotechnology been receiving favorable news coverage?
Media coverage about PRAN stock has trended somewhat positive on Monday, Accern Sentiment Analysis reports. The research group rates the sentiment of press coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Prana Biotechnology earned a daily sentiment score of 0.20 on Accern's scale. They also gave media headlines about the biotechnology company an impact score of 46.66 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the next several days. View Recent Headlines for Prana Biotechnology.
How do I buy shares of Prana Biotechnology?
Shares of PRAN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Prana Biotechnology's stock price today?
One share of PRAN stock can currently be purchased for approximately $2.04.
How big of a company is Prana Biotechnology?
Prana Biotechnology has a market capitalization of $19.31 million and generates $100,000.00 in revenue each year. The biotechnology company earns $-5,680,000.00 in net income (profit) each year or ($0.64) on an earnings per share basis. Prana Biotechnology employs 9 workers across the globe.
How can I contact Prana Biotechnology?
Prana Biotechnology's mailing address is LEVEL 2 369 ROYAL PARADE, PARKVILLE C3, 3052. The biotechnology company can be reached via phone at 61-3-9349-4906 or via email at [email protected]
MarketBeat Community Rating for Prana Biotechnology (NASDAQ PRAN)
MarketBeat's community ratings are surveys of what our community members think about Prana Biotechnology and other stocks. Vote "Outperform" if you believe PRAN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PRAN will underperform the S&P 500 over the long term. You may vote once every thirty days.
